Galmed Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary

Eocene

16/11/2022 23:02

* Galmed Pharmaceuticals Ltd  GLMD.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 16 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Galmed Pharmaceuticals Ltd's reported EPS for the quarter
was a
loss of 21 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Galmed Pharmaceuticals Ltd shares had risen by 7.2% this
quarter and lost 81.7% so far this year.
    * The company reported a quarterly loss of $5.35 million.
    * Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $1.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
16 at 11:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.16          -0.21          Missed
 Jun. 30 2022      -0.24          -0.15          Beat
 Mar. 31 2022      -0.32          -0.24          Beat
 Dec. 31 2021      -0.30          -0.30          Met